AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27135476 — intervention group
Group type: COMPARATOR
Intervention: Control group (C), standard soccer conditioning regimen
Number of subjects: 28
Study 24529064 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-125 thin seeds
Number of subjects: 18
Study 24529064 — intervention group
Group type: COMPARATOR
Intervention: Standard I-125 stranded seeds
Number of subjects: 18
Study 22207414 — intervention group
Group type: EXPERIMENTAL
Intervention: Acorn extract (2 g)
Number of subjects: 12
Study 22207414 — intervention group
Group type: COMPARATOR
Intervention: Galantamine (16 mg)
Number of subjects: 12
Study 22207414 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 12
Study 20422704 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg daily for 5 days
Number of subjects: 118
Study 20422704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 17415689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse synchronized pneumotonometry (PNT)
Number of subjects: 78
Study 17415689 — intervention group
Group type: COMPARATOR
Intervention: Routine pneumotonometry (PNT)
Number of subjects: 78
Study 17415689 — intervention group
Group type: EXPERIMENTAL
Intervention: PNT (both pulse synchronized and routine)
Number of subjects: 78
Study 17415689 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometry (GAT)
Number of subjects: 78
Study 15791671 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light (405 nm) delivered at 40 J/cm2 to a 1-cm diameter spot in the gastric antrum
Number of subjects: 10
Study 15791671 — intervention group
Group type: COMPARATOR
Intervention: Control spots (not treated with blue light)
Number of subjects: 10
Study 11791035 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI alone (fosinopril 20 mg/day)
Number of subjects: 10
Study 11791035 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB alone (irbesartan 150 mg/day)
Number of subjects: 10
Study 11791035 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ACEI + ARB
Number of subjects: 10
Study 11791035 — intervention group
Group type: COMPARATOR
Intervention: Baseline (without medication)
Number of subjects: 10
Study 10457137 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate (SLS) challenges
Number of subjects: 0
Study 10457137 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline surface hydration
Number of subjects: 0
Study 10457137 — intervention group
Group type: EXPERIMENTAL
Intervention: Single and iterative SLS challenges
Number of subjects: 0
Study 10457137 — intervention group
Group type: EXPERIMENTAL
Intervention: Single water- or SLS-patch-tests
Number of subjects: 0
Study 7781843 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (NA)
Number of subjects: 80
Study 7781843 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (NA) + Cyclosporin (CyA)
Number of subjects: 80
Study 7781843 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 2141274 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic sodium chloride (2 litres)
Number of subjects: 0
Study 2141274 — intervention group
Group type: COMPARATOR
Intervention: Ringer lactate solution (2 litres)
Number of subjects: 0
Study 7470518 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback‐assisted HR lowering task (FG)
Number of subjects: 27
Study 7470518 — intervention group
Group type: COMPARATOR
Intervention: Unassisted HR lowering task (ICG)
Number of subjects: 27
Study 7470518 — intervention group
Group type: COMPARATOR
Intervention: Relaxation period (RCG)
Number of subjects: 27
Study 31654268 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss and lifestyle intervention
Number of subjects: 288
Study 28600734 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (2 mg/day)
Number of subjects: 77
Study 28600734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 25588767 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (5 Hz, 3000 pulses per day for 10 days)
Number of subjects: 4
Study 25588767 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (3000 pulses per day for 10 days)
Number of subjects: 4
Study 24413845 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with an angular stable implant
Number of subjects: 50
Study 24413845 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 50
Study 24413845 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 50
Study 22865576 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin sinonasal rinses (MUP)
Number of subjects: 25
Study 22865576 — intervention group
Group type: COMPARATOR
Intervention: Saline rinses (CON)
Number of subjects: 25
Study 20677478 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at specialized prenatal clinics for Native American women (both rural and urban locations)
Number of subjects: 154
Study 20677478 — intervention group
Group type: COMPARATOR
Intervention: Control group (not attending specialized prenatal clinics)
Number of subjects: 154
Study 18004930 — intervention group
Group type: EXPERIMENTAL
Intervention: En masse retraction
Number of subjects: 30
Study 18004930 — intervention group
Group type: COMPARATOR
Intervention: Two-step retraction
Number of subjects: 30
Study 15958334 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (single dose) prior to TACE
Number of subjects: 60
Study 15958334 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic antibiotics (NONE group)
Number of subjects: 60
Study 11990744 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume of exercise with carbohydrate-protein supplementation
Number of subjects: 7
Study 11990744 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate volume of exercise with carbohydrate-protein supplementation
Number of subjects: 7
Study 11990744 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume of exercise with carbohydrate-protein supplementation
Number of subjects: 7
Study 11990744 — intervention group
Group type: COMPARATOR
Intervention: High volume of exercise with placebo
Number of subjects: 7
Study 11990744 — intervention group
Group type: COMPARATOR
Intervention: Moderate volume of exercise with placebo
Number of subjects: 7
Study 11990744 — intervention group
Group type: COMPARATOR
Intervention: Low volume of exercise with placebo
Number of subjects: 7
Study 11990744 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-protein supplementation
Number of subjects: 7
Study 11990744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 9667603 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoE epsilon4 allele frequency in FTD patients
Number of subjects: 33
Study 9667603 — intervention group
Group type: COMPARATOR
Intervention: ApoE epsilon4 allele frequency in early-onset Alzheimer's disease (EOAD) patients
Number of subjects: 33
Study 9667603 — intervention group
Group type: COMPARATOR
Intervention: ApoE epsilon4 allele frequency in late-onset Alzheimer's disease (LOAD) patients
Number of subjects: 33
Study 9667603 — intervention group
Group type: COMPARATOR
Intervention: ApoE epsilon4 allele frequency in non-demented elderly controls
Number of subjects: 33
Study 8208596 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosurf Neonatal (5 mL/kg)
Number of subjects: 34
Study 8208596 — intervention group
Group type: EXPERIMENTAL
Intervention: Survanta (4 mL/kg)
Number of subjects: 34
Study 8208596 — intervention group
Group type: COMPARATOR
Intervention: Control (no surfactant administration)
Number of subjects: 34
Study 2645569 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation (45 mg/L)
Number of subjects: 37
Study 2645569 — intervention group
Group type: COMPARATOR
Intervention: Control (less than 5 mg/L taurine)
Number of subjects: 37
Study 28742612 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Sleep (SS; 6.5 hours/night in bed)
Number of subjects: 24
Study 28742612 — intervention group
Group type: COMPARATOR
Intervention: Healthy Sleep Opportunity (HS; 9.5 hours/night in bed)
Number of subjects: 24
Study 26824933 — intervention group
Group type: EXPERIMENTAL
Intervention: FP 250 μg MDI with Mini Spacer
Number of subjects: 0
Study 26824933 — intervention group
Group type: COMPARATOR
Intervention: FP 250 μg MDI with Aerochamber
Number of subjects: 0
Study 26824933 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC 25/250 μg with Mini Spacer
Number of subjects: 0
Study 26824933 — intervention group
Group type: COMPARATOR
Intervention: SFC 25/250 μg with Aerochamber
Number of subjects: 0
Study 25896737 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational Process Improvement Intervention (OPII)
Number of subjects: 1509
Study 25896737 — intervention group
Group type: COMPARATOR
Intervention: Delayed-Start condition
Number of subjects: 1509
Study 24046993 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketofol (1-1.5 mg/kg propofol with 0.25 mg/kg ketamine)
Number of subjects: 40
Study 24046993 — intervention group
Group type: COMPARATOR
Intervention: Propofol (1-1.5 mg/kg)
Number of subjects: 40
Study 20071105 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline treatment
Number of subjects: 626
Study 18936702 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (target blood glucose 4.4‐6.1 mmol/L or 80‐110 mg/dL)
Number of subjects: 523
Study 18936702 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (target blood glucose 10‐11.1 mmol/L or 180‐200 mg/dL)
Number of subjects: 523
Study 18936702 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 523
Study 18936702 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 523
Study 17201701 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of major antiepileptic drugs (AEDs)
Number of subjects: 150
Study 17201701 — intervention group
Group type: COMPARATOR
Intervention: Continuation of major antiepileptic drugs (AEDs)
Number of subjects: 150
Study 17201701 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of carbamazepine (CBZ)
Number of subjects: 150
Study 17201701 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of valproate (VPA)
Number of subjects: 150
Study 14998083 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid (2.2 g)
Number of subjects: 360
Study 14998083 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (2 g)
Number of subjects: 360
Study 11889279 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention (support groups and one-on-one contacts with peer advocates)
Number of subjects: 0
Study 11889279 — intervention group
Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 0
Study 9459032 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertext tutorial
Number of subjects: 2
Study 9459032 — intervention group
Group type: COMPARATOR
Intervention: Conventional lecture
Number of subjects: 2
Study 7933040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic evaluation of esophagogastric junction and alimentary tract diameter in patients with sliding hiatal hernia.
Number of subjects: 30
Study 7933040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic signs (non-visualization of the esophagogastric junction and diameter greater than 16 mm) evaluated in a prospective study of 38 patients.
Number of subjects: 30
Study 7933040 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (18 patients)
Number of subjects: 30
Study 2834746 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole for 1 day
Number of subjects: 59
Study 2834746 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole for 2 days
Number of subjects: 59
Study 2834746 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole for 3 days
Number of subjects: 59
Study 31217143 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated logistic clinical SYNTAX score
Number of subjects: 4006
Study 28495681 — intervention group
Group type: EXPERIMENTAL
Intervention: Single RDTs for HIV and syphilis
Number of subjects: 2214
Study 28495681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual RDTs for HIV and syphilis
Number of subjects: 2214
Study 25475927 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational Emotive Behavior Therapy (REBT)
Number of subjects: 34
Study 25475927 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study 23298603 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C9 mutant individuals (MT group; CYP2C9*2 and *3)
Number of subjects: 100
Study 23298603 — intervention group
Group type: COMPARATOR
Intervention: CYP2C9 wild-type individuals (WT group; CYP2C9*1)
Number of subjects: 100
Study 20839290 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneous injections every 6 months for 3 years)
Number of subjects: 160
Study 20839290 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous injections every 6 months for 3 years)
Number of subjects: 160
Study 17443126 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 mg transdermal nicotine
Number of subjects: 60
Study 17443126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17136583 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BT‐B) intravesical injections (5000 MU, 1 ml, diluted to 20 mls with normal saline, injected in 10 different sites into the detrusor)
Number of subjects: 20
Study 17136583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12616259 — intervention group
Group type: EXPERIMENTAL
Intervention: MNT protocol care (MNT‐PC)
Number of subjects: 394
Study 12616259 — intervention group
Group type: COMPARATOR
Intervention: Usual nutrition care (UC)
Number of subjects: 394
Study 10675165 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination of health-care workers
Number of subjects: 1437
Study 10675165 — intervention group
Group type: COMPARATOR
Intervention: No influenza vaccination of health-care workers
Number of subjects: 1437
Study 9091670 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentive and peer-support group
Number of subjects: 286
Study 9091670 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-support group only
Number of subjects: 286
Study 9091670 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentive only
Number of subjects: 286
Study 9091670 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 286
Study 9091670 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 286
Study 29600688 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on robot-assisted gait training using the Lokomat
Number of subjects: 74
Study 29600688 — intervention group
Group type: COMPARATOR
Intervention: Add-on conventional overground gait training
Number of subjects: 74
Study 29600688 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on robot-assisted gait training
Number of subjects: 74
Study 26211411 — intervention group
Group type: EXPERIMENTAL
Intervention: Double volume exchange transfusion (DVET)
Number of subjects: 83
Study 26211411 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ST)
Number of subjects: 83
Study 24424070 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (n = 339)
Number of subjects: 683
Study 24424070 — intervention group
Group type: COMPARATOR
Intervention: No erythropoietin (n = 344)
Number of subjects: 683
Study 24424070 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin with autologous reinfusion (n = 214)
Number of subjects: 683
Study 24424070 — intervention group
Group type: COMPARATOR
Intervention: No erythropoietin with autologous reinfusion (n = 206)
Number of subjects: 683
Study 24424070 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 683
Study 24424070 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood reinfusion
Number of subjects: 683
Study 22703892 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 10mg / Morphine 20mg
Number of subjects: 0
Study 22703892 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 15mg / Morphine 30mg
Number of subjects: 0
Study 22703892 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 20mg / Morphine 40mg
Number of subjects: 0
Study 22703892 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 40mg
Number of subjects: 0
Study 22703892 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (all doses)
Number of subjects: 0
Study 22703892 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 20mg and 30mg
Number of subjects: 0
Study 22703892 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 40mg and Oxycodone (all doses)
Number of subjects: 0
Study 19199542 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine plus sulfadoxine‐pyrimethamine
Number of subjects: 129
Study 16961805 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole group: 7-day course of lansoprazole 30 mg, amoxicillin 750 mg, and metronidazole 250 mg, b.i.d.
Number of subjects: 61
Study 16961805 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine group: 7-day course of famotidine 40 mg, amoxicillin 750 mg, and metronidazole 250 mg, b.i.d.
Number of subjects: 61
Study 15285122 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature-matching similarity measure model
Number of subjects: 0
Study 15285122 — intervention group
Group type: COMPARATOR
Intervention: ALCOVE model
Number of subjects: 0
Study 11600165 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement interventions for depression care; specific interventions not detailed.
Number of subjects: 0
Study 11600165 — intervention group
Group type: COMPARATOR
Intervention: Not applicable; control group not specified.
Number of subjects: 0
Study 9424603 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 9424603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering medication
Number of subjects: 0
Study 7963709 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (200 mg every 4 h)
Number of subjects: 0
Study 7963709 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent dideoxycytidine (ddC) (0.03 mg/kg every 4 h)
Number of subjects: 0
Study 7963709 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine and dideoxycytidine given in alternating weeks
Number of subjects: 0
Study 7963709 — intervention group
Group type: COMPARATOR
Intervention: Intermittent zidovudine
Number of subjects: 0
Study 3307888 — intervention group
Group type: EXPERIMENTAL
Intervention: Grenz rays in a total dose of 900 rad (9 Gy) given in three equal doses at 21‐day intervals
Number of subjects: 30
Study 3307888 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy given in a similar treatment schedule
Number of subjects: 30
Study 31772064 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) therapy (60 L/min) for 15 min
Number of subjects: 18
Study 31772064 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen (O2) therapy for 15 min
Number of subjects: 18
Study 28910768 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed image synthesis algorithm
Number of subjects: 0
Study 28910768 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation framework for generation performance
Number of subjects: 0
Study 28817828 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training augmented by VR (TT+VR)
Number of subjects: 281
Study 28817828 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training alone (TT)
Number of subjects: 281
Study 26654101 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine (PQ) with Artesunate (AS)
Number of subjects: 180
Study 26654101 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine (PQ) with Artesunate-Pyronaridine (AS-PYR)
Number of subjects: 180
Study 26654101 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine (PQ) with Dihydroartemisinin-Piperaquine (DHA-PP)
Number of subjects: 180
Study 26654101 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (AS) followed by Primaquine (PQ)
Number of subjects: 180
Study 22701039 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual work support (up to eight individually targeted vocational sessions in conjunction with group rehabilitation for low back pain)
Number of subjects: 51
Study 22701039 — intervention group
Group type: COMPARATOR
Intervention: Group rehabilitation (control group)
Number of subjects: 51
Study 19762159 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 14
Study 19762159 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 14
Study 18419825 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml/kg normal saline (Ns group, n = 32)
Number of subjects: 94
Study 18419825 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml/kg 3.5% sodium chloride (Hs group, n = 30)
Number of subjects: 94
Study 18419825 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml/kg 5% sodium bicarbonate (Sb group, n = 32)
Number of subjects: 94
Study 18419825 — intervention group
Group type: COMPARATOR
Intervention: Control group (Ns and Hs)
Number of subjects: 94
Study 16768639 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (1.5 mg/day)
Number of subjects: 50
Study 16768639 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (200 mg/day)
Number of subjects: 50
Study 16768639 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg/day)
Number of subjects: 50
Study 16768639 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 14984503 — intervention group
Group type: EXPERIMENTAL
Intervention: IV anti-D
Number of subjects: 6
Study 14984503 — intervention group
Group type: COMPARATOR
Intervention: IV immunoglobulin (IVIG)
Number of subjects: 6
Study 11053917 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg/g ointment (twice daily)
Number of subjects: 114
Study 11053917 — intervention group
Group type: COMPARATOR
Intervention: Dithranol cream (0.25-2%, once daily for 30 min)
Number of subjects: 114
Study 9057430 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day treatment with bismuth, metronidazole, and tetracycline
Number of subjects: 30
Study 9057430 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day treatment with bismuth, metronidazole, and tetracycline
Number of subjects: 30